Polymer-based drugs are a unique class of therapeutics proven through more than 50 years of clinical development and successful treatments for a wide range of applications.

Glyscend is pioneering a new generation of orally administered polymer therapies known as mucus complexing polymers (MCPs). These MCPs use electrostatic and covalent interactions to enable complexation with mucin, the primary component of intestinal mucus, in a pH dependent manner.

Using an array of approaches including surface plasmon resonance, in vivo assays, and animal models, a select group of polymeric compounds were identified and optimized to meet key criteria:

The efficacy of MCPs have been tested acutely and chronically in relevant animal models.

We are focused on treating metabolic diseases with our MCP platform and are actively expanding our pipeline to include programs that address topical GI as well as other metabolic, inflammatory, and autoimmune conditions.

Currently, Glyscend products are limited to investigational use only.